The Canada Pension Plan Investment Board is acquiring a US$1.3 billion stake in LifeArc’s royalty interests on worldwide sales of immunotherapy drug Keytruda through its European credit group. The drug, which is intended to help the body fight certain forms of cancer, was developed by Merck Sharp & Dohme Corp. and has been approved in 85 countries. […]